CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $102,000 | -28.7% | 20,000 | 0.0% | 0.02% | 0.0% |
| Q2 2019 | $143,000 | -73.7% | 20,000 | -51.2% | 0.02% | -77.9% |
| Q1 2019 | $544,000 | +72.7% | 41,000 | +2.5% | 0.10% | +31.6% |
| Q4 2018 | $315,000 | -43.1% | 40,000 | -20.0% | 0.08% | +5.3% |
| Q3 2018 | $554,000 | -17.4% | 50,000 | 0.0% | 0.08% | -25.7% |
| Q2 2018 | $671,000 | -31.2% | 50,000 | -33.3% | 0.10% | -30.8% |
| Q1 2018 | $975,000 | -78.8% | 75,000 | -85.0% | 0.15% | -73.9% |
| Q4 2017 | $4,600,000 | +712.7% | 500,000 | +612.1% | 0.56% | +645.3% |
| Q3 2017 | $566,000 | -2.4% | 70,210 | -30.1% | 0.08% | +56.2% |
| Q2 2017 | $580,000 | +346.2% | 100,420 | +232.4% | 0.05% | +140.0% |
| Q1 2017 | $130,000 | +400.0% | 30,210 | +98.6% | 0.02% | +400.0% |
| Q4 2016 | $26,000 | – | 15,210 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |